WO2007066698A1 - 抗perp遺伝子組換え抗体 - Google Patents
抗perp遺伝子組換え抗体 Download PDFInfo
- Publication number
- WO2007066698A1 WO2007066698A1 PCT/JP2006/324385 JP2006324385W WO2007066698A1 WO 2007066698 A1 WO2007066698 A1 WO 2007066698A1 JP 2006324385 W JP2006324385 W JP 2006324385W WO 2007066698 A1 WO2007066698 A1 WO 2007066698A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antibody
- amino acid
- acid sequence
- seq
- replaced
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 136
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 121
- 229920001184 polypeptide Polymers 0.000 claims abstract description 116
- 101150000754 PERP gene Proteins 0.000 claims abstract description 87
- 235000000346 sugar Nutrition 0.000 claims abstract description 81
- 108091035707 Consensus sequence Proteins 0.000 claims abstract description 68
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 24
- 201000011510 cancer Diseases 0.000 claims abstract description 22
- 201000010099 disease Diseases 0.000 claims abstract description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 10
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 422
- 210000004027 cell Anatomy 0.000 claims description 245
- 108020004414 DNA Proteins 0.000 claims description 156
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 105
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 105
- 230000004048 modification Effects 0.000 claims description 90
- 238000012986 modification Methods 0.000 claims description 90
- 125000000539 amino acid group Chemical group 0.000 claims description 84
- 239000013598 vector Substances 0.000 claims description 73
- 239000003814 drug Substances 0.000 claims description 30
- 210000004408 hybridoma Anatomy 0.000 claims description 29
- 238000004519 manufacturing process Methods 0.000 claims description 25
- 229940124597 therapeutic agent Drugs 0.000 claims description 17
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 12
- 230000006798 recombination Effects 0.000 claims description 12
- 239000004480 active ingredient Substances 0.000 claims description 4
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 3
- 238000006471 dimerization reaction Methods 0.000 claims description 3
- 102000007079 Peptide Fragments Human genes 0.000 claims 1
- 108010033276 Peptide Fragments Proteins 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 abstract description 168
- 230000027455 binding Effects 0.000 abstract description 85
- 101001127470 Homo sapiens p53 apoptosis effector related to PMP-22 Proteins 0.000 abstract description 77
- 102100030898 p53 apoptosis effector related to PMP-22 Human genes 0.000 abstract description 47
- 102000045488 human PERP Human genes 0.000 abstract description 25
- 238000011282 treatment Methods 0.000 abstract description 12
- 238000011161 development Methods 0.000 abstract description 3
- 238000000034 method Methods 0.000 description 129
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 111
- 239000012634 fragment Substances 0.000 description 90
- 239000013604 expression vector Substances 0.000 description 88
- 238000006243 chemical reaction Methods 0.000 description 81
- 239000002299 complementary DNA Substances 0.000 description 74
- 241000699666 Mus <mouse, genus> Species 0.000 description 73
- 235000001014 amino acid Nutrition 0.000 description 68
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 67
- 229940024606 amino acid Drugs 0.000 description 67
- 230000000694 effects Effects 0.000 description 67
- 150000001413 amino acids Chemical class 0.000 description 66
- 239000002609 medium Substances 0.000 description 61
- 239000013612 plasmid Substances 0.000 description 61
- 125000002842 L-seryl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])O[H] 0.000 description 58
- 239000000243 solution Substances 0.000 description 52
- 239000000427 antigen Substances 0.000 description 48
- 108091007433 antigens Proteins 0.000 description 48
- 102000036639 antigens Human genes 0.000 description 48
- 235000018102 proteins Nutrition 0.000 description 45
- 102000004169 proteins and genes Human genes 0.000 description 44
- 241000024188 Andala Species 0.000 description 37
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 37
- 108091008146 restriction endonucleases Proteins 0.000 description 36
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 34
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 33
- 230000009257 reactivity Effects 0.000 description 27
- 210000004102 animal cell Anatomy 0.000 description 26
- 230000035772 mutation Effects 0.000 description 25
- 238000002360 preparation method Methods 0.000 description 24
- 241000588724 Escherichia coli Species 0.000 description 23
- 238000012258 culturing Methods 0.000 description 20
- 239000000872 buffer Substances 0.000 description 19
- 239000002773 nucleotide Substances 0.000 description 19
- 125000003729 nucleotide group Chemical group 0.000 description 19
- 239000012228 culture supernatant Substances 0.000 description 18
- 239000012636 effector Substances 0.000 description 18
- 230000014509 gene expression Effects 0.000 description 17
- 108020004705 Codon Proteins 0.000 description 16
- 108091028043 Nucleic acid sequence Proteins 0.000 description 16
- 238000010367 cloning Methods 0.000 description 16
- 238000000605 extraction Methods 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 15
- 239000000047 product Substances 0.000 description 15
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 14
- 238000002835 absorbance Methods 0.000 description 14
- 238000010276 construction Methods 0.000 description 14
- 239000012091 fetal bovine serum Substances 0.000 description 14
- 230000001900 immune effect Effects 0.000 description 14
- 238000005259 measurement Methods 0.000 description 14
- 239000007758 minimum essential medium Substances 0.000 description 14
- 241000894006 Bacteria Species 0.000 description 13
- 239000004698 Polyethylene Substances 0.000 description 12
- 238000001962 electrophoresis Methods 0.000 description 12
- 230000004927 fusion Effects 0.000 description 12
- 230000036541 health Effects 0.000 description 12
- 241000282693 Cercopithecidae Species 0.000 description 11
- 210000000628 antibody-producing cell Anatomy 0.000 description 11
- -1 disulfide amino acid Chemical class 0.000 description 11
- 108020004999 messenger RNA Proteins 0.000 description 11
- 241000206602 Eukaryota Species 0.000 description 10
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 10
- 108010076504 Protein Sorting Signals Proteins 0.000 description 10
- 229940079593 drug Drugs 0.000 description 10
- 238000000684 flow cytometry Methods 0.000 description 10
- 239000000499 gel Substances 0.000 description 10
- 239000006228 supernatant Substances 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 9
- 206010035226 Plasma cell myeloma Diseases 0.000 description 9
- 239000012980 RPMI-1640 medium Substances 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 238000005516 engineering process Methods 0.000 description 9
- 238000010369 molecular cloning Methods 0.000 description 9
- 201000000050 myeloid neoplasm Diseases 0.000 description 9
- 238000000746 purification Methods 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- 241000282412 Homo Species 0.000 description 8
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 8
- 238000005119 centrifugation Methods 0.000 description 8
- 230000001472 cytotoxic effect Effects 0.000 description 8
- 229940088598 enzyme Drugs 0.000 description 8
- 230000001965 increasing effect Effects 0.000 description 8
- 201000005202 lung cancer Diseases 0.000 description 8
- 208000020816 lung neoplasm Diseases 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 238000005215 recombination Methods 0.000 description 8
- 108091034117 Oligonucleotide Proteins 0.000 description 7
- 238000000246 agarose gel electrophoresis Methods 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 238000013461 design Methods 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- 239000008187 granular material Substances 0.000 description 7
- 238000009396 hybridization Methods 0.000 description 7
- 108020004707 nucleic acids Proteins 0.000 description 7
- 102000039446 nucleic acids Human genes 0.000 description 7
- 150000007523 nucleic acids Chemical class 0.000 description 7
- 238000010186 staining Methods 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 230000029087 digestion Effects 0.000 description 6
- 238000004520 electroporation Methods 0.000 description 6
- 230000003248 secreting effect Effects 0.000 description 6
- 238000012163 sequencing technique Methods 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 5
- 206010009944 Colon cancer Diseases 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 5
- 241000620209 Escherichia coli DH5[alpha] Species 0.000 description 5
- 208000000277 Splenic Neoplasms Diseases 0.000 description 5
- 230000007910 cell fusion Effects 0.000 description 5
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 5
- 238000005094 computer simulation Methods 0.000 description 5
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 239000012894 fetal calf serum Substances 0.000 description 5
- 230000002068 genetic effect Effects 0.000 description 5
- 238000002649 immunization Methods 0.000 description 5
- 230000003053 immunization Effects 0.000 description 5
- 210000004379 membrane Anatomy 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- 201000002471 spleen cancer Diseases 0.000 description 5
- 229920000936 Agarose Polymers 0.000 description 4
- 206010003445 Ascites Diseases 0.000 description 4
- 108020004635 Complementary DNA Proteins 0.000 description 4
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 4
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 4
- WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 108060003951 Immunoglobulin Proteins 0.000 description 4
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 4
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 4
- 101100407723 Mus musculus Perp gene Proteins 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 239000006285 cell suspension Substances 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000002163 immunogen Effects 0.000 description 4
- 102000018358 immunoglobulin Human genes 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 238000013508 migration Methods 0.000 description 4
- 230000005012 migration Effects 0.000 description 4
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- XOJVVFBFDXDTEG-UHFFFAOYSA-N pristane Chemical compound CC(C)CCCC(C)CCCC(C)CCCC(C)C XOJVVFBFDXDTEG-UHFFFAOYSA-N 0.000 description 4
- 230000009465 prokaryotic expression Effects 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 230000010473 stable expression Effects 0.000 description 4
- 238000007447 staining method Methods 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 230000009466 transformation Effects 0.000 description 4
- 230000001131 transforming effect Effects 0.000 description 4
- 238000011144 upstream manufacturing Methods 0.000 description 4
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 3
- 241000699800 Cricetinae Species 0.000 description 3
- 241000701022 Cytomegalovirus Species 0.000 description 3
- 239000007760 Iscove's Modified Dulbecco's Medium Substances 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 238000012181 QIAquick gel extraction kit Methods 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 238000012300 Sequence Analysis Methods 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 238000012136 culture method Methods 0.000 description 3
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 3
- 210000000805 cytoplasm Anatomy 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000003113 dilution method Methods 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000013613 expression plasmid Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 238000002523 gelfiltration Methods 0.000 description 3
- 239000011544 gradient gel Substances 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 159000000003 magnesium salts Chemical class 0.000 description 3
- 239000003607 modifier Substances 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000012521 purified sample Substances 0.000 description 3
- 230000002285 radioactive effect Effects 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 230000002269 spontaneous effect Effects 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 239000013589 supplement Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 230000005030 transcription termination Effects 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- OOIBFPKQHULHSQ-UHFFFAOYSA-N (3-hydroxy-1-adamantyl) 2-methylprop-2-enoate Chemical compound C1C(C2)CC3CC2(O)CC1(OC(=O)C(=C)C)C3 OOIBFPKQHULHSQ-UHFFFAOYSA-N 0.000 description 2
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 2
- LPXQRXLUHJKZIE-UHFFFAOYSA-N 8-azaguanine Chemical compound NC1=NC(O)=C2NN=NC2=N1 LPXQRXLUHJKZIE-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 108010084313 CD58 Antigens Proteins 0.000 description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 2
- 229920002271 DEAE-Sepharose Polymers 0.000 description 2
- 101150074155 DHFR gene Proteins 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 2
- 108010019236 Fucosyltransferases Proteins 0.000 description 2
- 229930182566 Gentamicin Natural products 0.000 description 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 102100030984 Lymphocyte function-associated antigen 3 Human genes 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 108091081021 Sense strand Proteins 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 108091081024 Start codon Proteins 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- 108010022394 Threonine synthase Proteins 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 238000003916 acid precipitation Methods 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 229960003896 aminopterin Drugs 0.000 description 2
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 2
- 235000011130 ammonium sulphate Nutrition 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 210000003567 ascitic fluid Anatomy 0.000 description 2
- 229960000074 biopharmaceutical Drugs 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 229960004397 cyclophosphamide Drugs 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 238000012215 gene cloning Methods 0.000 description 2
- 229960002518 gentamicin Drugs 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 229940027941 immunoglobulin g Drugs 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000012516 mab select resin Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 210000005087 mononuclear cell Anatomy 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 238000011275 oncology therapy Methods 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000006320 pegylation Effects 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 229940066827 pertussis vaccine Drugs 0.000 description 2
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- YEENEYXBHNNNGV-XEHWZWQGSA-M sodium;3-acetamido-5-[acetyl(methyl)amino]-2,4,6-triiodobenzoate;(2r,3r,4s,5s,6r)-2-[(2r,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound [Na+].CC(=O)N(C)C1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I.O[C@H]1[C@H](O)[C@@H](CO)O[C@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 YEENEYXBHNNNGV-XEHWZWQGSA-M 0.000 description 2
- 210000004988 splenocyte Anatomy 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000010474 transient expression Effects 0.000 description 2
- 238000002424 x-ray crystallography Methods 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
- UHEPSJJJMTWUCP-DHDYTCSHSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-[(1r)-1-hydroxyethyl]oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;sulfuric acid Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H]([C@@H](C)O)O2)N)[C@@H](N)C[C@H]1N UHEPSJJJMTWUCP-DHDYTCSHSA-N 0.000 description 1
- PLVPPLCLBIEYEA-WAYWQWQTSA-N (z)-3-(1h-indol-3-yl)prop-2-enoic acid Chemical compound C1=CC=C2C(\C=C/C(=O)O)=CNC2=C1 PLVPPLCLBIEYEA-WAYWQWQTSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- 101150028074 2 gene Proteins 0.000 description 1
- NKDFYOWSKOHCCO-YPVLXUMRSA-N 20-hydroxyecdysone Chemical compound C1[C@@H](O)[C@@H](O)C[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@@](C)(O)[C@H](O)CCC(C)(O)C)CC[C@]33O)C)C3=CC(=O)[C@@H]21 NKDFYOWSKOHCCO-YPVLXUMRSA-N 0.000 description 1
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 1
- SNQBJBVXPVCDLA-UHFFFAOYSA-N 5-[[3-propan-2-yloxy-5-(2-thiophen-3-ylethoxy)benzoyl]amino]-1,3,4-thiadiazole-2-carboxylic acid Chemical compound C=1C(C(=O)NC=2SC(=NN=2)C(O)=O)=CC(OC(C)C)=CC=1OCCC=1C=CSC=1 SNQBJBVXPVCDLA-UHFFFAOYSA-N 0.000 description 1
- YSFGBPCBPNVLOK-UHFFFAOYSA-N 6-hydroxy-2-methylhex-2-enamide Chemical compound NC(=O)C(C)=CCCCO YSFGBPCBPNVLOK-UHFFFAOYSA-N 0.000 description 1
- 229960005508 8-azaguanine Drugs 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 241000588832 Bordetella pertussis Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 244000056139 Brassica cretica Species 0.000 description 1
- 235000003351 Brassica cretica Nutrition 0.000 description 1
- 235000003343 Brassica rupestris Nutrition 0.000 description 1
- QLNSPJMIYWEWNF-UHFFFAOYSA-N CC(C)CCCC(C)CCCC(C)CCCC(C)C.CC(C)CCCC(C)CCCC(C)CCCC(C)C Chemical compound CC(C)CCCC(C)CCCC(C)CCCC(C)C.CC(C)CCCC(C)CCCC(C)CCCC(C)C QLNSPJMIYWEWNF-UHFFFAOYSA-N 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 238000000018 DNA microarray Methods 0.000 description 1
- 108010053187 Diphtheria Toxin Proteins 0.000 description 1
- 102000016607 Diphtheria Toxin Human genes 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 241001452028 Escherichia coli DH1 Species 0.000 description 1
- 241001131785 Escherichia coli HB101 Species 0.000 description 1
- 241001302584 Escherichia coli str. K-12 substr. W3110 Species 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- MURGITYSBWUQTI-UHFFFAOYSA-N Fluorescin Natural products OC(=O)C1=CC=CC=C1C1C2=CC=C(O)C=C2OC2=CC(O)=CC=C21 MURGITYSBWUQTI-UHFFFAOYSA-N 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 235000016623 Fragaria vesca Nutrition 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- LQEBEXMHBLQMDB-UHFFFAOYSA-N GDP-L-fucose Natural products OC1C(O)C(O)C(C)OC1OP(O)(=O)OP(O)(=O)OCC1C(O)C(O)C(N2C3=C(C(N=C(N)N3)=O)N=C2)O1 LQEBEXMHBLQMDB-UHFFFAOYSA-N 0.000 description 1
- LQEBEXMHBLQMDB-JGQUBWHWSA-N GDP-beta-L-fucose Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@@H]1OP(O)(=O)OP(O)(=O)OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C3=C(C(NC(N)=N3)=O)N=C2)O1 LQEBEXMHBLQMDB-JGQUBWHWSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010071602 Genetic polymorphism Diseases 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 1
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 1
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 101150102264 IE gene Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 238000012218 Kunkel's method Methods 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 241000272168 Laridae Species 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000282553 Macaca Species 0.000 description 1
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 108090000157 Metallothionein Proteins 0.000 description 1
- 102000003792 Metallothionein Human genes 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000714177 Murine leukemia virus Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 101000822667 Mus musculus Something about silencing protein 10 Proteins 0.000 description 1
- BKAYIFDRRZZKNF-VIFPVBQESA-N N-acetylcarnosine Chemical compound CC(=O)NCCC(=O)N[C@H](C(O)=O)CC1=CN=CN1 BKAYIFDRRZZKNF-VIFPVBQESA-N 0.000 description 1
- 229930182474 N-glycoside Natural products 0.000 description 1
- 229920001007 Nylon 4 Polymers 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 108010026552 Proteome Proteins 0.000 description 1
- 239000012979 RPMI medium Substances 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 108010039491 Ricin Proteins 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 235000016127 added sugars Nutrition 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940024546 aluminum hydroxide gel Drugs 0.000 description 1
- SMYKVLBUSSNXMV-UHFFFAOYSA-K aluminum;trihydroxide;hydrate Chemical compound O.[OH-].[OH-].[OH-].[Al+3] SMYKVLBUSSNXMV-UHFFFAOYSA-K 0.000 description 1
- 238000012197 amplification kit Methods 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 238000011861 anti-inflammatory therapy Methods 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- LFYJSSARVMHQJB-QIXNEVBVSA-N bakuchiol Chemical compound CC(C)=CCC[C@@](C)(C=C)\C=C\C1=CC=C(O)C=C1 LFYJSSARVMHQJB-QIXNEVBVSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000003181 biological factor Substances 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 238000010805 cDNA synthesis kit Methods 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 238000005277 cation exchange chromatography Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- HOECDSKYSXKRKE-UHFFFAOYSA-M cesium;2,2,2-trifluoroacetic acid;thiocyanate Chemical compound [Cs+].[S-]C#N.OC(=O)C(F)(F)F HOECDSKYSXKRKE-UHFFFAOYSA-M 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- VDQQXEISLMTGAB-UHFFFAOYSA-N chloramine T Chemical compound [Na+].CC1=CC=C(S(=O)(=O)[N-]Cl)C=C1 VDQQXEISLMTGAB-UHFFFAOYSA-N 0.000 description 1
- 238000011098 chromatofocusing Methods 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 235000021310 complex sugar Nutrition 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- ZINJLDJMHCUBIP-UHFFFAOYSA-N ethametsulfuron-methyl Chemical compound CCOC1=NC(NC)=NC(NC(=O)NS(=O)(=O)C=2C(=CC=CC=2)C(=O)OC)=N1 ZINJLDJMHCUBIP-UHFFFAOYSA-N 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000003209 gene knockout Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 210000002288 golgi apparatus Anatomy 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 102000055277 human IL2 Human genes 0.000 description 1
- 102000057041 human TNF Human genes 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 229940040731 human interleukin-12 Drugs 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 150000005165 hydroxybenzoic acids Chemical class 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- PLVPPLCLBIEYEA-UHFFFAOYSA-N indoleacrylic acid Natural products C1=CC=C2C(C=CC(=O)O)=CNC2=C1 PLVPPLCLBIEYEA-UHFFFAOYSA-N 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 238000001155 isoelectric focusing Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000008095 long lasting therapeutic effect Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 238000010841 mRNA extraction Methods 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 229960004961 mechlorethamine Drugs 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical class ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 102000035118 modified proteins Human genes 0.000 description 1
- 108091005573 modified proteins Proteins 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 235000010460 mustard Nutrition 0.000 description 1
- 231100000219 mutagenic Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 210000001322 periplasm Anatomy 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920002523 polyethylene Glycol 1000 Polymers 0.000 description 1
- 229940113116 polyethylene glycol 1000 Drugs 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- YVSWPCCVTYEEHG-UHFFFAOYSA-N rhodamine B 5-isothiocyanate Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=C(N=C=S)C=C1C(O)=O YVSWPCCVTYEEHG-UHFFFAOYSA-N 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 150000003839 salts Chemical group 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 201000002314 small intestine cancer Diseases 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 229960004355 vindesine Drugs 0.000 description 1
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
Definitions
- 0003 P P gene is coupled to (which is referred to as an anti-P P body below) by the C of P P gene.
- human chimera since it is produced using a human chimera or a gene assembly technique, it can be produced as a morphological child. For example, if a class is used as the human body (denoted as below) (denoted as C area below) (the C area is denoted as C), antibody cells (below denoted as CC) It is possible to produce human chimeras and
- the C 2 in the body is at least the modification that replaces the s at position 9 of the Ano sequence shown in Sequence 45 with another, and the replacement of Se at the position Se with another.
- the e of the 3rd to 35th sequence is represented by the e of the 3rd, the Se of the 3rd, the Po of the 4th to Pe, the s of the 44th to s, and the 45th.
- the body or antibody according to (3) The body or antibody according to (3).
- the piece is a piece selected from ab ab, (ab), one piece (sc), (abod), dissi (s), and C (((23).
- the body structure is s 62 at the 4th position in the Ano sequence shown in array 2.
- Figure 22 shows the SSPG (using 5 to 2 ginger) purified PPC. Is the case and is the result of the case. , Both 9 and 9 are molecular units, 2 are PP chimera 348, and 3 to 8 are anti-P PC e. Each.
- the chain portion 25 a is shown.
- 144 shows the reactivity of the prepared PP bodies to PP human PC g in cytometh.
- Cells the horizontal axis is degrees.
- C the responsiveness of the PP human body with anomalous residue is shown.
- the reactivity to PP was shown using a body that recognizes the area of PP in cytometh.
- the number in the graph is 382 responsiveness.
- the reactivity of 382 was defined as the reactivity of 382 to PP. Reactivity with PP or PP at time () is shown.
- the enzyme has a basic sequence represented by the sequence as follows under the stringent conditions: ⁇ Idition, pray-dose, Southern-dye, Eq. It means the obtained ability, specifically, using a PC or a glass with a row or PC, if it has a row or a row of PC or slide glass fixed, After performing the exercise on sodium, C, use ⁇ 2 degree SC (consisting of 5 degree sodium, 5 degree sodium, 5 degree sodium of f degree SC), and iterate under C cases. You can improve what you can do by washing the slides.
- the anoic acid on the ano sequence represented by 002 2 has a substituted or added ano sequence is oec a Co
- G (Cos o O e a) is 5 in the base sequence
- a in the sequence is (Cos o e e d a) is 2 in the base sequence
- (Pe a o ceo de s a c) in the sequence is
- the regions corresponding to the 35th to 75th and the 3rd to 54th positions in the array of arrays shown by Sequence 2 are shown by Sequence 2 when using e ⁇ 2.
- the region corresponding to the 36th to 76th and 29th to 47th of the Ano row is the cell region.
- the values used for prediction are the values used for these programs.
- an epidemiological method for cells expressed by the PP gene is used, and a fixed source such as a fluorescent color method is expressed.
- a method for confirming the compatibility of the somatic body with the cell-specific source is preferably used. Physically, the color method described in Reference (24) can be mentioned.
- cells obtained by the gene assembly technique include cells expressing po, which are obtained by introducing a vector containing a po-containing c into an animal cell or the like. Specifically, there is a cell in which the PP gene plus cP P described in the reference is introduced to express a po.
- CC 2 and C 3 of the body are 3 and 5, respectively, and CC and 2 of the antibody are C 2 and C 3, respectively.
- the Akira gene construct includes a human chimeric body, a human body, a human body, an antibody fragment, and the like, which are produced by gene assembly. In the gene assembly, it has the characteristics of knuckle body, low antigen, and prolonged blood phase reduction. Are preferred as therapeutic agents.
- human chimera of the present invention include a human chimera of which the antibody has an amino acid sequence of sequences 4 to 9.
- the human and non-human body C and A in the human body were transplanted into the human body at and at different positions.
- the human body can be produced by constructing a human body expression vector by inserting the above into an animal vector having C and a gene encoding C in the human body, and expressing the vector by inserting into the animal.
- any one can be used as long as it is an ortho sequence of a human body and an ortho sequence of a human body.
- An array of body and body groups is used.
- the C of 004 body any of those belonging to n may be used, but those of G class are preferable, and G G2 G3 G4 belonging to G class
- the amino acid of the antibody is represented by the deviation of sequences 3 to 35, or the deviation of the antibodies of sequence 3 to 35 is represented by Se 4 of G 27 of G 27 Po Po of the 44th, s of the 45th, e of the 49th, a of the 72nd, and a of the 97th, in which at least one anno is replaced by another, and Is an array shown in array 36, or an array shown in array 36 G of 3rd, 5th of 35th “42nd a 46th e 9th s 7th P e 7th And at least 77 selected from the e of the 77th column is a group of columns in which at least one group is replaced by another group.
- G of 27 is P e
- P of 4 is P e
- s of 44 is s
- G of 45 is e
- e of 49 is e
- a of 72 is, and An in which the a of the 97th is replaced by
- G of 27 is P e
- Se of 3 is
- P o of 4 is P e
- s of 44 is s
- G of 45 is, a of 72 is, and 97 Ocular an with a replaced by
- G of 27 is P e, Se of 3 is, P o of 4 is P e, G of 45 is e, e of 49 is e, a of 72 is, and 97 An with the a of the eye replaced by
- the introduced amino acids of 6 are, specifically, the ones represented by the deviations of sequences 3 to 35
- G of 27 was replaced by P e
- P of 4 was replaced by P e
- G of 45 was replaced by e
- e of 49 was replaced by e
- a of 72 was replaced by and a of 97 was replaced by.
- G of the 27th is replaced by P e
- s of the 44th is replaced by s
- G of the 45th is replaced by e
- e of 49th is replaced by e
- a of 72nd is replaced by a
- a of 97th is replaced by.
- G of 27 was replaced by P e
- Se of 3 was replaced by P e of 4 was replaced by P e
- s of 44 was replaced by s
- a of 72 was replaced by, and a of 97 was replaced by.
- the 27th G is replaced by P e
- the 3rd Se is replaced by
- the 44th s is replaced by s
- the 49th e is replaced by e
- the 72nd a is replaced by
- the 97th Aa is replaced by.
- G of the 27th is replaced by P e
- s of the 44th is replaced by s
- G of the 45th is replaced by a
- G of the 27th is replaced by P e
- G of the 45th is replaced by e
- e of the 49th is replaced by e
- a of the 72nd is replaced by a
- a of the 97th is replaced by
- G of the 27th to P e Se of the 3rd to G, G of the 45th to, a of the 72nd to and a of the 97th to, and
- the introduced amino acid of 005 03 is specifically the amino acid shown by the deviation of sequences 3 to 35.
- the introduced amino acid of 005 48 is specifically the amino acid shown in Sequence 36.
- the third G is a, the fifth is e, the 35th is Pe, the a is 42, the s is 69, the s is Se, the seventh Pe is, and the seventh is To Se, and the substitution of e of the 77th e with e,
- the introduced amino acid of 006 56 is specifically the amino acid shown in Sequence 36.
- the third G is replaced by a, the fifth by e, the 35th by P e, the 42 a by Se, the 46th e by, and the seventh P e replaced by. ,
- the third G is replaced by a
- the fifth is replaced by e
- the 35th is replaced by Pe
- the 46th e is replaced by the seventh Pe
- the 77th e replaced by e.
- the third G is replaced by a, the fifth by e, the 42nd by Se, the 46th by e, the 7th by Pe, and the 77th by e. ,
- the introduced amino acid of 005 7 specifically includes the amino acid shown in Sequence 36.
- the fifth is replaced by e
- the 35th is replaced by P e
- the 42nd a is replaced by Se
- the 46th e is replaced by
- the 7th Pe is replaced by
- the 42nd a is replaced by Se
- the 46th e is replaced by s
- the 69th s is replaced by Se
- the 7th Pe is replaced by ⁇
- the 7th is replaced by Se.
- the third G is replaced by a, the 35th is replaced by Pe, the 46th e is replaced by, and the seventh Pe is replaced by
- the third G is replaced by a, the 42nd a by Se, the 46th e by and the seventh P e replaced by
- the fifth is replaced by e
- the 35th is replaced by P e
- the 46th e is replaced by
- the 7th P e is replaced by
- the 5th is replaced with e
- the 42nd a is replaced by Se
- the 46th e is replaced by
- the 7th Pe is replaced by
- the third G replaced by a, the fifth by e, the 46th by e, and the seventh P e replaced by
- An example is an ano series in which the 42nd a is replaced by Se, the 46th e is replaced by, and the 7th Pe is replaced by.
- the introduced amino acid of 006 02 is specifically the amino acid shown in Sequence 36.
- the introduced amino acid of 006 1 is specifically shown in SEQ ID NO: 36.
- the clear body specifically includes the different ano sequences shown in sequences 58 to 63, but preferably the different ano sequences shown in sequences 58 59 6 62 and 63. And more preferably the sequence represented by SEQ.
- Examples of the clear body include the body consisting of and having the above-mentioned ano series.
- Array 53 has the ano sequence represented by array 59 array 53 has the ano sequence represented by array 6 array 55 has the ano sequence represented by array 62 but array 5 is the array Has an array represented by 58 Human having sequence No. 53 having the sequence shown in sequence 58 human has sequence No. 53 having sequence shown in sequence 63 but sequence No. 56 having sequence No. shown in sequence 62 has sequence No. 53 An example is a body having the amino acid sequence shown in Sequence 62. More preferred is
- Clarifications include ab (ab) ab Sc dabod ds and C.
- 006 ab is a piece of (chain of 22 obtained by treating G with white matter It is cleaved at the 4th ano), and is a fragment with a resistance of 50,000 molecules in which one half of the chain and the body are bound together.
- 006 4 (ab) has a molecular resistance of 2 ab, which is composed by combining two conjugate parts of the range of G in Pep. It is a mentor.
- Ming (ab) can be made with the following ab or a combination.
- B of light which does not have a consensus sequence that binds to the region of light, specifically recognizes the structure of the region of the region expressed by the PP gene, and detects and of the gene construct that binds to the region c Can be expressed and produced by inserting the ab fragment of the body into a product vector or a product vector, and inserting the vector into a product vector.
- 006 Sc is a piece of P or P that is an antigenicity obtained by linking a book and a book using an appropriate window marker (hereinafter referred to as P).
- Ming's dabod constructs the drive of sc such that the anolog of P is under 8 and inserts into either the product vector or into the product vector and inserts the vector into or into. And can be manufactured.
- 006 ds is the one obtained by substituting each of the above with an anosine, and then connecting via a stain bond.
- the antibody can be selected based on the body structure of the antibody according to the method described by Ano e e et al. For substitution with stain (Po eee 7 697 (994)).
- Include C of Ming is a gene that specifically recognizes the body structure of the region of the region expressed by the PP gene that has no consensus sequence that binds to the region of Ming, and Construct a vector and put into a product vector or into a product vector and store a vector It can be expressed and manufactured by packaging.
- radioisotopes examples include 21 and the like, which can be bound to the body by, for example, the Clan method.
- a method of binding a daunoine body a method of binding a noino body's amino group via glutaldehyde, or a method of coupling a daunoine's group to an amino group via water solubility. The method etc. are given.
- cytokines that activate immune cells, such as human interface 2, human quarts, and human quarts.
- the agent used may be a label used in usual epidemiological or standard methods.
- examples include qualities such as acocatase, peokida, and laze, qualities such as austenite and tin, and qualities such as online (C) R C.
- any one can be used as long as it can express the gene of interest such as large intestine and animal cell.
- the vector used is one that can be autonomous or chromosomal in the host cell to be used and contains a suitable vector in a position capable of transcribing the polynucleotide.
- a suitable vector in a position capable of transcribing the polynucleotide.
- the kuta is autonomous while being a pect, a bot, a knot that includes a row and a row.
- the kuta may also contain genes that control it.
- putters derived from large intestine and the like such as putter (P) ac putter, P putter, P putter, and 7 putter
- P putter
- P putter P putter
- P putter P putter
- 7 putter can be given.
- artificially designed filters such as tandem filters with two rows of P, parameters, ac 7 parameters, and e parameters can also be used.
- a plus which is adjusted to an appropriate distance (for example, 6 to 8) from the start of the in-dagger (S e a a o) which is the body sequence as the above-mentioned rectifier.
- the base sequence of the sequence will be optimal for the host.
- the group can be substituted with, which can improve the target.
- large intestine e large intestine 2 e, large intestine, large intestine C, large intestine 3276, large intestine W 485, large intestine J 9 , Large intestine, large intestine o 49, large intestine W, large intestine 49, etc. can be used.
- any method can be used as long as it is the method of introducing the above.
- the method of using um ions Poc a cad Sc S 69 2 (972) Ge e 7 7 (982) oec a Ge The method described in ea Ge e cs 68 (979) can be cited.
- po When produced in the large intestine, po can be expressed in the formula such that it is soluble in the cytoplasm, insoluble in the cytoplasm, or soluble in the Plascus sp. .
- Cytomega Wis (C) eda e ea
- S 4 putter Towe putter
- meta-imputer hitopter
- S You can give them some things.
- 008 is human (a a a),
- the transformant obtained as described above is cultivated on the ground,
- an indexer may be added to the soil if necessary.
- soupi may be added to the soil when using microorganisms that have been replaced with ac-actuator, and indo-acetic acid may be added to the soil when using microorganisms that have been converted using putters.
- the recombinants such as microorganisms and animal cells that possess the cultivated bacterium, which are clarified, are cultured according to the usual method to produce po. By, it is possible to manufacture
- a host there are various methods for producing a host, such as a method of producing in a host, a method of secreting in a host, and a method of producing above, and an appropriate method can be selected depending on the host cell to be used. In addition, it may be produced by expressing it as a po in a white matter with any white matter.
- the purification can be carried out by a single method or a combination of methods such as a chromatographic method using a gas, a gas, etc., a method using a molecule, a method using an actogram, a cut, a motion, etc.
- the cells When po is formed insoluble in the cytoplasm and expressed, the cells are similarly recovered and then centrifuged to recover the solubility of po. Soluble in collected white matter Soluble in white matter. By diluting or diluting the liquid, the white matter is restored to a normal three-dimensional structure, and then the product can be obtained by the same production method as above.
- the conductor such as 0096 or its body is secreted into cells, the conductor such as the upper port or its body can be recovered.
- d a ced C e ec, Kin P a aca Po e ec oo s e, S ece e a, Pe Se e, Shimadzu, etc.
- a suitable agent eg, India's Agent (Co eeedsa) ammonium hydroxide pertussis vaccine. If is a part, an animal (e), ee (e oc a), etc., and a protein are prepared and used as immunity.
- the reaction of the protein with the antigen was determined by the standard method such as bodes abo aoaa (Cod S abo abo ao 9 88.)
- the antibody showed sufficient antibody titer against the used source.
- the source of the cells is a mouse, rat or musta.
- the cells containing cells such as the immunized mouse, rat, or musta are taken out 3 to 7 days after the antigen, and the antibody cells are collected. If you use a
- the above-mentioned myelocytes were mixed with or (PS) (Natrium 83, Nka.2, Saline 7.65, G., 7 2), cells and antibody 5 to 4 and centrifuged (2, 5). After discarding the cells, loosening the precipitated cells, and then, using C, add Poignry (PG) 2 2 and Methis 7 2 to 2 to one cell, and After repeating 2 several times, add the ground so that the total amount becomes 5. (9, 5), discard the cells, loosen the cells, and gently blow them out with a female pet. Suspend in ground OO plus xanthine (o), gin (5X o), and anten (o).
- PS Proliferhine
- gin gin
- anten o
- the following methods can be used as methods for specifically recognizing the body structure of the region that is expressed by the P P gene and selecting the one that produces the body that binds to the region.
- Nokuna 34 As an example of an id producing Nokuna, which recognizes the body structure of the region, there is Id3 producing Nokuna 34.
- Ylide 34 is attached as P 8643 at the Research Center for Industrial Science and Technology, Research Center (6, Higashi, Higashi, Japan), based on the Tapes agreement with the date of June 24, Heisei.
- the gene arrangement in the 0113 region can be determined, for example, by querying c of the body and as follows. Body ano, above. It can be determined by deducing from the gene sequence or by directly analyzing the antibody using a scanner. . a Co b o a o a a Seco d d o (Cod S abo abo a o P ess 989
- the antibody region is c Show how to play.
- the c is synthesized by extracting the protein that produces the mouse body.
- the generated c is clanged into a plus or other knucker to make a c-liner.
- the C of a us field is the one with a fraction of, or the cage with the c of is a plus.
- the base sequence and each of the amino acid sequences of and.
- the method for preparing the cells is an guandine eosod zo.543 (987), and the method for preparing the cells is the o (a) odized cesium column oec a Co abo aoaa. Seco ddo (Cod S abo abo ao Pess 989) and the like.
- a kit for preparing cells as ac soa o (o e) Q c Pe P f ca o (P a ac), etc. may be mentioned.
- a conventional method oec a Co abo aoaa Seco ddo (Cod Sa bo a bo ao Pess 89) e Po ocos oec a oo) S ee 34, is a commercially available kit, for example, Se.
- the method using Sc Pas d S seo CS es sad Pas d Co (G CO) or ZPCS es s (S aaee) can be mentioned. Is a c-embedded cector. Anything can be used.
- any one can be used as long as it can introduce, express and retain the c-lyer.
- e S ae es 5 8 (992) C6 Ge e cs 39 44 (954) 88 9 Sce ce 222 778 (983) 522 oo 66 (983) 8 2U oo 6 8 (966) 5 Ge e 38 27 (985 ) Is used. 0119 C As a c-kun of the body of a non-human body, such as a human being, the isotope is the recognized one. ⁇ The idea is the plaque idea oec a Co abo.
- aoaa Seco ddo Cod Sa bo abo ao Pess 989.
- c is prepared by preparing the ply, and c e is used as a mold.Po e ase C a Reac o PC oec a Co abo aoaa Seco ddo Cod S abo abo ao P ess (989) e Po ocos oec a oo S ee
- Cut c selected by 0120 method with appropriate restriction, esc
- the region of the body, particularly C is an important region that defines the original compatibility of the antibody. Therefore, it is possible that the affinity of the antibody for any of the groups in the antibody range, especially C, may be altered. Therefore, when creating a region that does not have the above-mentioned consensus sequence, it is necessary to modify it to an ano sequence that does not change the original compatibility of the antibody.
- the physical method is shown below. In order to change the consensus s that binds to the 0125 region and the amino acid sequence that does not change the compatibility of the Se or the body of the body, changes that directly affect the body structure of the antibody or the body structure of the antibody. It is necessary to exclude the alterations that influence and indirectly affect the antigen.
- an antigen that may affect the compatibility of the antigen is excluded. It is of utmost importance to measure how efficiently the mutations in Therefore, X U ⁇ o ⁇ 2 535 (977) is the body structure of the body due to the computer Poe ee 7 5 (994) and so on. However, based on the information on the body structures of these antibodies, there is a possibility that the compatibility of the antibody origin may differ depending on the region of the antibody, particularly C. Therefore, when introducing a mutation, it is necessary to make a variant and study the relationship with the modification of anoic acid.
- a column for designing the amino acid sequence in the region where the mutation is introduced is designed. Based on the measured columns, synthesize a different number of before and after, and use them to create a PC. In this case, it is preferable to design a total of 6 PCs and a PC that can be created.
- the amplified product is determined by adding esc S () (S aaee) or the like to determine the nucleotide sequence by the method described in (), and the sensation sequence that binds to the antibody region is present.
- a plus is obtained containing c with a sequence that encodes the sequence of regions of a different gene. Make sure that.
- a positive base sequence containing an amino acid in the 0129 region and a gene having a sequence which is a sequence of the gene sequence obtained in the above-mentioned manner is determined by the method described in this (). Confirm that it has been applied. 0130 (3) Gene assembly
- a somatic expression vector in which the C and C of the human body are incorporated is an animal vector in which the C and C of the human body are incorporated, and the C and C of the human body are added to the animal vector. Can be built by singing each.
- C of human body It can be C and C of any human body, for example, C of human body class and C of class.
- a color body composed of xontone and c can be used, but it is preferable to use c.
- any vector can be used, so long as it can express the gene encoding the C region of the human body in combination.
- G 7 (C o ec o ⁇ 3 3 (99)
- G 3 (oc e 3 7 (987)
- SG274 (Ge e 27 223 (984))
- C (Poc a ca Sc S 78 527 (98))
- SG bd2 4 (C o ec o 4 73 (99))
- S Sed 3 C o ec o / 3 79 (993)
- Vectors used for vector include S4's pattern U ⁇ oce ⁇ 37 (987)), Us blood disease virus's (oc eos es Co ⁇ 49 96 (987)), and immunogen. Examples include chain printers (Ce 4 479 (985)) and sensors (Ce 1 33 7 7 (983)).
- Human body C and C-containing, but integrated somatic expression vectors can be used with either the antibody and the type in which the chain is on a different vector or on the same vector (tandem). However, due to the construction of human body expression vectors, the introduction of animal cells, the transfer of chains in animals, and the like, the tandem-type human bodies containing C and C are incorporated. Expression vectors are preferred U. oe ods 67 27 (994)). Examples of somatic expression vectors in which tandem type human C and C-dosing are incorporated include X WO 97 354) 8 (b do a 7 559 (998)).
- the C and C of the human body as described in (3) are incorporated into the body expression vector in which the C or C of the human body is incorporated into the body of the human body, respectively.
- Each of these clones can be cloned to construct a human chimera expression vector.
- each c of the non-human body or is composed of the three base sequences of the non-human body or of the human body C or the five base sequences of C.
- a human chimeric expression vector can be constructed so that each gene is expressed in an appropriate form in each gene stream.
- the c in the human body can be constructed as follows.
- any human body can be used as long as it is natural.
- a human body or a human body registered in a database such as Po eaaa or a human body or a human body group of a human body.
- Se ces (99) and the like in order to produce a human C-body with sufficient pouring, homology () of the target non-human body is sufficient. In particular, it is desirable to select an array that has each 6).
- the desired human body or ortho cell array is planted with the desired non-human body or C cell cell array, and the human body or ortho cell array is respectively planted.
- the calculated Ano sequence is converted into a sequence by taking into account the frequency of use found in the base sequence of the body's genes, and it is converted into a sequence of the human body. Select each column to add the column of or. Based on the measured row, Later we synthesize a number of and use them to perform the PC method. [0135] Also, by introducing an appropriate restriction element sequence at the five ends of the synthesis located at both ends, the somatic expression vector constructed in (3) can be easily cunged with a c or a somatic expression. .
- the sequence of PC and amplification is determined by adding esc S () (S aaee), etc. to the plus, respectively, and the nucleotide sequence is determined by the method described in (). To get a plus.
- the C of the constructed body is added to the C or C gene of the human body of the integrated body expression vector.
- Kung and human expression vector can be constructed respectively.
- the human chimera body or body expression vector described in (3) 3 and (3) 5 was used to evaluate the human chimera body or body transientness. You can do the present.
- any cell can be used as long as it is a human chimera or a host capable of expressing the body, and further, CO 7 (CC C) is commonly used.
- CO 7 CC C
- Examples of cds Res CC ess 283 (99) CS 7 cell vectors include estran e ods cec cds Res CC ess 283 (99) kon P oc a cad Sc S 84 74 3 (987).
- An example of a cell vector is Ct pon 2 25789 Co ec oo 3 33 (99).
- the host into which the human chimera expression vector or the somatic expression vector is introduced may be any cell as long as it is a host capable of expressing the human chimera or the somatic expression vector.
- Us SP2 4 (CC C 58)
- Us P3X63 8 653 (CC C 8)
- Examples include gene-deficient C O (WO 5 35586) and rat 23 P2 G 62 (CC C 662).
- 0144 cell white matter such as enzymes involved in the formation of cell quo GPs, and white matter such as enzymes involved in the 6th position of guan at the end of the gu It is also possible to use a host with reduced or decreased sex such as white matter involved in the body's transport, preferably a CO cell deficient in the 6th gene described in W 5 35586.
- a human chimera or a trait that stably expresses the body according to the method disclosed in 2 25789, G4 8 acid salt (below, G 4 8 It can be selected by selecting the place containing the drug such as SG). As the place, P 4 (oe), G (this pharmaceutical), X 3 (J), (1 oe), b do a S (oe), or each of these places such as cattle (below, S is noted), etc.
- G4 8 acid salt (below, G 4 8 It can be selected by selecting the place containing the drug such as SG).
- P 4 (oe), G (this pharmaceutical), X 3 (J), (1 oe), b do a S (oe), or each of these places such as cattle (below, S is noted), etc.
- It can be used to elevate the human body.
- Human chimera or traits that can be purified using ptain color can be purified using ptain color.
- other purification methods usually used for producing white matter can be used.
- it can be purified by filtration, ion chromatography, and combination.
- Manufactured human chimera body or body is antibody body, under poadhodge, SSPG notation ae 227 68 (97) Western Standard o oco a bod ⁇ es P ⁇ c ⁇ es ad ac ⁇ ce ⁇ d ed o cade • c Pess (996), bodes abo aoaa Cod S abo abo ao (988), etc.
- the original compatibility of the produced Ming gene or antibody fragment and the binding to PP can be determined by surface plasmin using S and Ca ceo • 1 oe • 36 373 (993) or Aco e. Cytotoxic activity against CC can be measured and evaluated for CC properties, CC e ⁇ 36 373 (993). In addition, these effects are uniquely recognized in the body structure of the region which is produced by the PP gene and is not produced by the Ming gene assembly and described in the above-mentioned by introducing the modification into the region. Then
- Oxygen that has this activity can damage cells expressing a specific source, and thus can be used as a therapeutic drug for diseases.
- oral administration or oral administration such as buccal, respiratory tract, rectal, subcutaneous, intramuscular and intramuscular administration can be performed. , If desired, can be given intravenously.
- the forms include, capsules, agents, capsules, emulsions, loci, injections, tapes, and the like.
- Suitable agents for oral administration include injections, suppositories, agents and the like.
- Ordinary dose is usually ⁇ 8 depending on the purpose, administration, administration method, treatment duration, age, body weight, etc.
- the consensus of 0158 is an array consisting of s at the 59th position, Se at the 6th position, and Se at the 6th position in the array shown in array 2.
- C 2 has the array shown in array 45. To do.
- the sequence shown by 45 it is an array consisting of the union sensation, the 9th sth eye and the 9th Se.
- the amino acid sequence represented by 0159 45 the amino acid at the 9th position is arbitrary, so Se at the 9th position and the Se position was modified.
- Existing senoces of poes of oo ca ees se e ea ada se ces (99) was analyzed using the method of mpunting.
- a ply having the base sequence shown in 22 to 27 below for introducing an anion and the ply having the sequence shown in sequence 28 are used to prepare PC.
- create array 24 e • 2 In order to produce sequence 25 e ⁇ 3, in order to produce sequence 23 e ⁇ 4, in order to produce sequence 22 e ⁇ 5, in order to produce sequence 26 e ⁇ 6, in order to produce sequence 26 e ⁇ 6, sequence 27
- Each of the (asks) described in (1) was used as a ply. At the 3 end of these 6 classes, there is a sequence of elements for X3 recombination described in (2) of Reference 2.
- the temperature of the PC was 72 C after 25 reaction cycles consisting of 94 3 heating, 94 3 heating, 58 C 3 heating, and 74 C heating.
- Ge e PC S se 97 (Applied Systems) was used.
- the size of the PC product obtained was 3 b.
- the reaction was performed according to the written description using eeao C Sec ec S Read Reac o (Pos ses), and the nucleotide sequence was analyzed by Kensa PS 37 of the same company, and the target modified variant expression was performed. I confirmed that the vector was obtained.
- the expression in the body was determined by the conventional method bod ee.
- 0169 is a cell PCg s Joa Of C which is a cell confirmed to express the expression of P P gene. I used e 395 (976).
- the PP chimera 348 described in Reference 2 was used as a control, and CC 4 276 (WO 64754) was used as a control.
- FIG. Shows the mean (), and the horizontal axis shows the antibody degree. All 6 bodies were shown to bind to PCg cells, which was of the antibody.
- the CC property of the variant obtained in 1. was determined as follows.
- P 4 S (CS was cultured using P 4 (m 2 oe), centrifuged and After the site was P 4 (oe) containing P 64 S (5) 5 S, the cell density was adjusted to 2X according to the CC site and used as the target solution.
- the pute was centrifuged, and the dehydrogenase () property of was measured by using o o c es () and obtaining the data according to the statement.
- the data for separation was obtained by using the CC land instead of the land and, and the data for the land separation was obtained by using the CC land instead of the target and.
- the data for the separation were obtained by using CC medium instead of the antibody and Kata, reacting by adding 5 go X solution 45 minutes before the completion of the reaction, and obtaining the same product as above. It was set by CC.
- the CC property was measured by the following formula using the PP chimera 348 described in Reference 2 as a control.
- the 27th G3th Se4th Po which is considered to change the dimension of the antigenic position in the OO's base group and influence the sex of the antibody.
- 44th s 45th G 49th e 72nd a, and 97th a, O 3rd G, 5th 35th 42nd a 46th e 7th P e, and 77 E of each was selected.
- at least the upper ANO sequence was changed to the one that exists in the same way as in Us 3, and the and of the modified field were designed.
- G at the 27th position in the ANO sequence indicated by the deviations of sequences 3 to 35 is designated as Pe
- Se at the third position is designated as P e
- Po at the fourth position is designated as Pe.
- the third G of the array shown in array 36 is a
- the fifth is e
- the 35 is Pe
- the a is Se
- the e is 46.
- the c which is the anod of the P P body designed in the implementation (), was constructed using a PC as follows.
- 0188 octets (64-67) will be final o
- the designed antibody was separated from the chain segment of the PP us 34 chain shown at the ⁇ 22th position in sequence 38 to form a complete antibody antibody.
- I converted the sequence of electrons into genes.
- the corresponding gene was determined.
- Design a base sequence of c that encodes the complete antibody range amino acid sequence by setting the determined gene, and then add a PC sequence at the 5-3 end.
- Including was added. Divide the measured base sequence into four base sequences from the 5 side (the base sequence has about 2 rows at its end), and arrange them in alternating order of sense and antisense strands. Synthetic octets (7-74) were synthesized.
- the thus obtained plus solution was used to transform a large intestine strain, a plus was prepared from the resulting trait, and the base sequence was analyzed using eeao C Sec S Read Reac o (ed o.). A plus S having the desired base sequence (57) was obtained.
- SW is changed from (a) (7) ⁇ Synthetic 75 to 78) having ano of xo, ply ply (aaa S zo) located at the end and 4 ply (aaa S zo) were subjected to PC reaction at 4 o.
- a PC ⁇ 8 5 gas, the target ⁇ 4 b near the piece of the gene was taken out using Ge e ac o (QG).
- the sec S () (bottom, S) processed by S a was tuned, and the target S (including S 58) was acquired.
- a ply composite (94) was used for PC reaction, and a 5-gene piece was obtained.
- a 3-gene piece was obtained using a 3-ply (aaa S zo) synthetic o93).
- a PC reaction was performed using these genes and ply 32 plies, and amplified gene fragments were extracted using Ge e ac o (QG). Then, it was subjected to elementary treatment with a peculiar restriction co and sW: ⁇ 85 gas, the target piece near 4 b was emitted using Ge e ac o (QG). The gene fragment was inserted into the open position of S incorporating the restriction sW sequence, and Kuta S 3 2 containing the desired gene (6) was obtained. did.
- the degree was measured with a calibrator.
- the P P human chimera 348 in Reference 2 or the 382 produced in the experiment was used.
- a normal human vein 5 was collected, and sodium () 5 was added and mixed.
- Mononuclear cells (P C) were separated according to the manual using o o e (CO). Centrifugation was carried out in the separated PC and CC sites 2, and the solution was used as a suitable solution.
- step (2) 5 (diluted to a cell ratio of 2) was added to the cuta solution prepared in 2.
- the modified body was set at 5 in CC ground, 5 was obtained by diluting 8 times with 5x from 3x, the total amount was 5, and it was 4 in C. , And the pute were centrifuged, and the dehydrogenase () property of was measured by using C o c es () and obtaining the data according to the statement.
- Separation data was obtained by using CC land instead of Kuta and, and Cta separation data was obtained by performing the same operation as above using CC land instead of target and.
- the cP P prepared in 1. was used as a template and was located in the vector Ply 2 and P P gene, and contained the mutant amino acid.
- the vector 8S 3 containing the 0226 P P gene was used as a model, and the peculiar restriction co and the o containing the sequence of d (45) were used for PC response to amplify the desired gene.
- the widened gene pieces were treated with the restriction co and d 1.
- the expression vector S c s which can contain c and s at the C-terminus of the protein, was treated with the restrictions co and d 1 and the amino acid was appropriately inserted to produce S P P.
- the expression vector SPP a was subjected to restriction treatment with the restriction co and d 1, and the obtained gene fragment was inserted into the co and d sites of c 3 ct and c c containing the desired PP (7). 3 ⁇ o Obtained PP.
- the vector prepared in the above 5 () and the P P vector cP P prepared in were transferred into CG44 (C86) by the Cottpon method to obtain the trait.
- G4 8 (Nacalai Tesque) was added at the end of 6 and cultivated to produce mutant P P, C O P P C O P P C C 2 C O G C O SQ, and C O.
- the binding property to was carried out by using fluorescence as follows.
- 0229 (5) has no consensus sequence to bind to, or 3X of each fresh PP body, or the trait that did the above.
- a solution in which the PP chimera was diluted for C (SPS, ⁇ 2, O ⁇ 5a) was dispensed with c and was subjected to 36 times.
- C P human G () (Beckon Ta) diluted 5 times with C
- the reaction consisted of 5 C for 3 hours and 72 C for 25 cycles and 72 C for 7 hours.
- the materials were separated with a gasse, and a piece of 6 b was taken out with G C S (O 2).
- C OPO Kuta was ligated with OPO Co (o e), and then the colon strain was transformed with P oc a cad Sc S 69 2 (972) of N et al.
- the plus was extracted from the obtained transformant using a plus kit (Gen), and S was added as a kung vector for adding the 3 cs sequence of the 0235 PP piece obtained with the plus CPP containing the human PP gene. It was made.
- 0239 cells were diluted with 3 fields containing 5 G4 8 so that the cells became 25. Aliquots of 2 were dispensed on 96 utts, and kuning was performed by the limit.
- the cells prepared in (2) were administered to 3 6 ab C mice with the whooping cough vaccine laboratory). Five minutes later every week. The more part of Usus was subjected to the color method using the cells whose body price is shown below, and it was measured with 8S stem (Applied ion system) and cytometer (Beckenta). The organs were removed after the final 3 days.
- the 0242 organ was thinned in (sse a ed) (), loosened with tweezers and centrifuged (25 X, 5).
- the thus-obtained sodium chloride (P 766) was added, and the blood cells were removed by processing ⁇ 2.
- the sample () was used in the field 3 for cell combination.
- 0243 color method using 2 3 cells (ooeccooe ssa ec oo) I used a cell.
- Scoed ed becc S Two to three cells were incubated with Inbitogen, and cells separated by S (Inbitogen) were suspended in the same place, and 3 cells were added to each 96 wells. The mouse serum as a primary body or X-ray on the needle, and the secondary body at 647 U.S.G.
- the 0250 water was centrifuged (2 X, 5) to remove solids.
- Cluster When the class of purified PP us 34 was determined by the S method using an iping kit, the class of PP us 34 was G.
- 0255 PC was heated at 94C for 5 minutes, 94C for 5 minutes, 72C for 3 minutes for reaction cycle 5, 94C for 5 minutes, 7C for 3 hours, and C for 3 hours. , 9.
- the somatic expression vector X3 was constructed as follows.
- the liquid was used to transform large intestine 5 (Yobo).
- a positive was prepared from the obtained trait kun, reacted according to the manual using eeao C ce Se S ec S Read Reac o (Po s ses), and the nucleotide sequence was analyzed by Kensa PS 37 of the same company, and the desired sequence was analyzed. It was confirmed that plus 3 g and 34 shown in 8 having a base sequence were obtained.
- the reaction was performed according to the manual using eeao C ce Se c S Read Reac o (Pos ses), and the nucleotide sequence was analyzed by the company's Kensa PS 37. It was confirmed that the pluses obtained by c were added.
- the trait 348 introduced with X3 was obtained.
- the results are shown in the figure.
- the PP chimera 348 produced was found to have a band of about 5 kilotons (hereinafter referred to as d) in the molecule under the conditions, and two bands of 5 d 25 d under the conditions.
- the G class is the molecule 5d, and under the condition the SS bond in the molecule is cleaved, and it is decomposed into chains with 5d and about 25d bodes abo aoaa Cod S abo abo ao C ae 4 (988) o oco a bodes P c es ad Pac ce cade c Pess ed (996) . It is shown in the amino acid sequence 29 of PP chimera 348.
- a cancer therapeutic agent using a gene or fragment, a vector comprising the gene or fragment, a method of a body comprising a transformant or a transformant obtained by transforming a vector. Will be provided.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06834140A EP1959009A4 (en) | 2005-12-06 | 2006-12-06 | GENETICALLY RECOMBINANT ANTI-PERP ANTIBODIES |
JP2007549159A JP5095416B2 (ja) | 2005-12-06 | 2006-12-06 | 抗perp遺伝子組換え抗体 |
CA002632419A CA2632419A1 (en) | 2005-12-06 | 2006-12-06 | Genetically recombinant anti-perp antibody |
AU2006323706A AU2006323706A1 (en) | 2005-12-06 | 2006-12-06 | Genetically recombinant anti-PERP antibody |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005-352297 | 2005-12-06 | ||
JP2005352297 | 2005-12-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2007066698A1 true WO2007066698A1 (ja) | 2007-06-14 |
Family
ID=38122844
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2006/324385 WO2007066698A1 (ja) | 2005-12-06 | 2006-12-06 | 抗perp遺伝子組換え抗体 |
Country Status (6)
Country | Link |
---|---|
US (1) | US8093362B2 (ja) |
EP (1) | EP1959009A4 (ja) |
JP (1) | JP5095416B2 (ja) |
AU (1) | AU2006323706A1 (ja) |
CA (1) | CA2632419A1 (ja) |
WO (1) | WO2007066698A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109391434A (zh) * | 2017-08-11 | 2019-02-26 | 中兴通讯股份有限公司 | 参考信号的配置方法及装置 |
JP2019534844A (ja) * | 2016-09-08 | 2019-12-05 | ウリィ・テクノロジーズ・コーポレーション | clec14aに特異的に結合する脱糖化抗体及びその用途 |
Citations (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5623587A (en) | 1979-08-03 | 1981-03-05 | Mitsuwa Seiki Co Ltd | Vane type compressor |
JPS58110600A (ja) | 1981-12-25 | 1983-07-01 | Kyowa Hakko Kogyo Co Ltd | ヒトβ型インタ−フエロン遺伝子を含む組みかえ体プラスミド |
JPS60221091A (ja) | 1983-12-21 | 1985-11-05 | Kyowa Hakko Kogyo Co Ltd | 新規プロモ−タ− |
JPS61178926A (ja) | 1984-03-06 | 1986-08-11 | Takeda Chem Ind Ltd | 化学修飾ペプチドホルモンおよびその製造法 |
JPS63299A (ja) | 1986-04-22 | 1988-01-05 | イミユネツクス・コ−ポレ−シヨン | ヒトg−csfタンパク質の発現 |
JPH02117920A (ja) | 1988-05-06 | 1990-05-02 | Sumitomo Pharmaceut Co Ltd | ポリエチレングリコール誘導体、修飾ペプチドおよびその製造方法 |
US4939094A (en) | 1985-08-28 | 1990-07-03 | Kyowa Hakko Kogyo Co., Ltd. | Fused antigen polypeptide |
JPH02227075A (ja) | 1988-09-29 | 1990-09-10 | Kyowa Hakko Kogyo Co Ltd | 新規ポリペプチド |
JPH02257891A (ja) | 1989-03-31 | 1990-10-18 | Kyowa Hakko Kogyo Co Ltd | 組換え動物細胞による蛋白質の製造 |
JPH0322979A (ja) | 1989-06-19 | 1991-01-31 | Kyowa Hakko Kogyo Co Ltd | 新規プラスミノーゲン活性化因子 |
JPH05336963A (ja) | 1991-12-17 | 1993-12-21 | Kyowa Hakko Kogyo Co Ltd | 新規α2→3シアリルトランスフェラーゼ |
JPH06205694A (ja) | 1992-09-07 | 1994-07-26 | Kyowa Hakko Kogyo Co Ltd | ヒト化抗体 |
WO1994023021A1 (en) | 1993-03-29 | 1994-10-13 | Kyowa Hakko Kogyo Co., Ltd. | α-1,3-FUCOSYLTRANSFERASE |
WO1997010354A1 (en) | 1995-09-11 | 1997-03-20 | Kyowa Hakko Kogyo Co., Ltd. | ANTIBODY AGAINTS α-CHAIN OF HUMAN INTERLEUKIN 5 RECEPTOR |
US5714350A (en) * | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
WO1998055508A2 (en) | 1997-06-03 | 1998-12-10 | Sagami Chemical Research Center | HUMAN PROTEINS HAVING TRANSMEMBRANE DOMAINS AND DNAs ENCODING THESE PROTEINS |
WO1999005446A1 (en) | 1997-07-21 | 1999-02-04 | Itsac N.V. | Connector assembly for a fluid connection |
WO2000055350A1 (en) | 1999-03-12 | 2000-09-21 | Human Genome Sciences, Inc. | Human cancer associated gene sequences and polypeptides |
WO2000055629A2 (en) | 1999-03-15 | 2000-09-21 | Eos Biotechnology, Inc. | Methods of diagnosing and treating breast cancer |
WO2001010883A1 (en) * | 1999-08-09 | 2001-02-15 | Massachusetts Institute Of Technology | Cell death gene and uses thereof |
WO2001022920A2 (en) | 1999-09-29 | 2001-04-05 | Human Genome Sciences, Inc. | Colon and colon cancer associated polynucleotides and polypeptides |
WO2001066719A1 (fr) | 2000-03-07 | 2001-09-13 | Chiba-Prefecture | Nouveau gene clone en neuroblastome humain et nouveaux fragments de gene |
WO2002000174A2 (en) | 2000-06-28 | 2002-01-03 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
WO2002047534A2 (en) | 2000-12-12 | 2002-06-20 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
WO2002060317A2 (en) | 2001-01-30 | 2002-08-08 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of pancreatic cancer |
US20020119463A1 (en) | 2000-07-28 | 2002-08-29 | Mary Faris | Prostate cancer markers |
US20030065157A1 (en) | 2001-04-04 | 2003-04-03 | Lasek Amy W. | Genes expressed in lung cancer |
US20030064947A1 (en) | 1998-03-18 | 2003-04-03 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
WO2005035586A1 (ja) | 2003-10-08 | 2005-04-21 | Kyowa Hakko Kogyo Co., Ltd. | 融合蛋白質組成物 |
WO2005121338A1 (ja) * | 2004-06-07 | 2005-12-22 | Kyowa Hakko Kogyo Co., Ltd. | 抗perp抗体 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1287129A1 (en) | 2000-05-19 | 2003-03-05 | F.Hoffmann-La Roche Ag | A process for determing the tumoricidal potential of a sample by the use of a nucleic acid which is downregulated in human tumor cells |
AU2002367318B2 (en) | 2002-01-02 | 2007-07-12 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
US20060286090A1 (en) * | 2005-04-21 | 2006-12-21 | Attardi Laura D | Mediators of epithelial adhesion and their role in cancer and skin disorders |
EP1790664A1 (en) * | 2005-11-24 | 2007-05-30 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against claudin-18 for treatment of cancer |
-
2006
- 2006-12-06 US US11/634,209 patent/US8093362B2/en not_active Expired - Fee Related
- 2006-12-06 AU AU2006323706A patent/AU2006323706A1/en not_active Abandoned
- 2006-12-06 WO PCT/JP2006/324385 patent/WO2007066698A1/ja active Application Filing
- 2006-12-06 EP EP06834140A patent/EP1959009A4/en not_active Withdrawn
- 2006-12-06 JP JP2007549159A patent/JP5095416B2/ja not_active Expired - Fee Related
- 2006-12-06 CA CA002632419A patent/CA2632419A1/en not_active Abandoned
Patent Citations (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5623587A (en) | 1979-08-03 | 1981-03-05 | Mitsuwa Seiki Co Ltd | Vane type compressor |
JPS58110600A (ja) | 1981-12-25 | 1983-07-01 | Kyowa Hakko Kogyo Co Ltd | ヒトβ型インタ−フエロン遺伝子を含む組みかえ体プラスミド |
US4686191A (en) | 1981-12-25 | 1987-08-11 | Hakko Kogyo Co., Ltd. Kyowa | Recombinant plasmid containing human interferon-beta gene |
JPS60221091A (ja) | 1983-12-21 | 1985-11-05 | Kyowa Hakko Kogyo Co Ltd | 新規プロモ−タ− |
JPS61178926A (ja) | 1984-03-06 | 1986-08-11 | Takeda Chem Ind Ltd | 化学修飾ペプチドホルモンおよびその製造法 |
US4939094A (en) | 1985-08-28 | 1990-07-03 | Kyowa Hakko Kogyo Co., Ltd. | Fused antigen polypeptide |
JPS63299A (ja) | 1986-04-22 | 1988-01-05 | イミユネツクス・コ−ポレ−シヨン | ヒトg−csfタンパク質の発現 |
JPH02117920A (ja) | 1988-05-06 | 1990-05-02 | Sumitomo Pharmaceut Co Ltd | ポリエチレングリコール誘導体、修飾ペプチドおよびその製造方法 |
JPH02227075A (ja) | 1988-09-29 | 1990-09-10 | Kyowa Hakko Kogyo Co Ltd | 新規ポリペプチド |
JPH02257891A (ja) | 1989-03-31 | 1990-10-18 | Kyowa Hakko Kogyo Co Ltd | 組換え動物細胞による蛋白質の製造 |
JPH0322979A (ja) | 1989-06-19 | 1991-01-31 | Kyowa Hakko Kogyo Co Ltd | 新規プラスミノーゲン活性化因子 |
US5160735A (en) | 1989-06-19 | 1992-11-03 | Kyowa Hakko Kogyo Co. Ltd. | Plasminogen activator |
JPH05336963A (ja) | 1991-12-17 | 1993-12-21 | Kyowa Hakko Kogyo Co Ltd | 新規α2→3シアリルトランスフェラーゼ |
US5714350A (en) * | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
JPH06205694A (ja) | 1992-09-07 | 1994-07-26 | Kyowa Hakko Kogyo Co Ltd | ヒト化抗体 |
WO1994023021A1 (en) | 1993-03-29 | 1994-10-13 | Kyowa Hakko Kogyo Co., Ltd. | α-1,3-FUCOSYLTRANSFERASE |
WO1997010354A1 (en) | 1995-09-11 | 1997-03-20 | Kyowa Hakko Kogyo Co., Ltd. | ANTIBODY AGAINTS α-CHAIN OF HUMAN INTERLEUKIN 5 RECEPTOR |
WO1998055508A2 (en) | 1997-06-03 | 1998-12-10 | Sagami Chemical Research Center | HUMAN PROTEINS HAVING TRANSMEMBRANE DOMAINS AND DNAs ENCODING THESE PROTEINS |
WO1999005446A1 (en) | 1997-07-21 | 1999-02-04 | Itsac N.V. | Connector assembly for a fluid connection |
US20030064947A1 (en) | 1998-03-18 | 2003-04-03 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
WO2000055350A1 (en) | 1999-03-12 | 2000-09-21 | Human Genome Sciences, Inc. | Human cancer associated gene sequences and polypeptides |
WO2000055629A2 (en) | 1999-03-15 | 2000-09-21 | Eos Biotechnology, Inc. | Methods of diagnosing and treating breast cancer |
WO2001010883A1 (en) * | 1999-08-09 | 2001-02-15 | Massachusetts Institute Of Technology | Cell death gene and uses thereof |
WO2001022920A2 (en) | 1999-09-29 | 2001-04-05 | Human Genome Sciences, Inc. | Colon and colon cancer associated polynucleotides and polypeptides |
WO2001066719A1 (fr) | 2000-03-07 | 2001-09-13 | Chiba-Prefecture | Nouveau gene clone en neuroblastome humain et nouveaux fragments de gene |
WO2002000174A2 (en) | 2000-06-28 | 2002-01-03 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
US20020119463A1 (en) | 2000-07-28 | 2002-08-29 | Mary Faris | Prostate cancer markers |
WO2002047534A2 (en) | 2000-12-12 | 2002-06-20 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
WO2002060317A2 (en) | 2001-01-30 | 2002-08-08 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of pancreatic cancer |
US20030065157A1 (en) | 2001-04-04 | 2003-04-03 | Lasek Amy W. | Genes expressed in lung cancer |
WO2005035586A1 (ja) | 2003-10-08 | 2005-04-21 | Kyowa Hakko Kogyo Co., Ltd. | 融合蛋白質組成物 |
WO2005121338A1 (ja) * | 2004-06-07 | 2005-12-22 | Kyowa Hakko Kogyo Co., Ltd. | 抗perp抗体 |
Non-Patent Citations (122)
Title |
---|
"Antibodies-A Laboratmy Manual", 1988, COLD SPRING HARBOR LABORATORY |
"Antibodies-A Laboratory Mamial", 1988, COLD SPRING HARBOR LABORATORY |
"Antibodies-A Laboratory manual", 1988, COLD SPRING HARBOR LABORATORY |
"Antibodies-A Laboratory Manual", vol. 14, 1988, COLD SPRING HARBOR LABORATORY |
"Antibody Engineering, A Practical Guide", 1992, W. H. FREEMAN AND COMPANY |
"Antibody Engneering, A Practical Guide", 1992, FREEMAN AND COMPANY |
"BLAST", J. MOL. BIOL., vol. 215, 1990, pages 403 |
"BLAST2", NUCLEIC ACIDS RES, vol. 25, 1997, pages 3389 |
"Current Protocols in Molecular Biology", 1987, JOHN WILEY & SONS |
"DNA Cloning, J: Core Techniques, A Practical Approach", 1995 |
"Methods in Nucleic Acids Res.", 1991, CRC PRESS, pages: 283 |
"Molecular Antibodies-Principles and Practice", 1996, ACADEMIC PRESS |
"Molecular Cloning, A Laboratory Mamual", 1989, COLD SPRING HARBOR LABORATORY PRESS |
"Molecular Cloning, A Laboratory Manual", 1989, COLD SPRING HARBOR LAB. PRESS |
"Molecular Cloning, A Laboratory Manual", 1989, COLD SPRING HARBOR LABORATORY PRESS |
"Monoclonal Anlibody Experiment Manual", 1987, KODANSHA SCIENTIFIC |
"Monoclonal Antibodies-Principles and practice", 1996, ACADEMIC PRESS |
"Monoclonal Antibody Experiment Manual", 1987, KODANSHA SCIENTIFIC |
AGRIC. BIOL. CHEM., vol. 53, 1989, pages 277 |
AGRICULTURAL BIOLOGICAL CHEMISTRY, vol. 48, 1984, pages 669 |
ARRTICANCER RESEARCH, vol. 20, 2000, pages 2801 |
ATCC CRL-1597: EUROPEAN JOURNAL OF IMMUNOLOGY, vol. 6, 1976, pages 511 |
ATTARDI L.D. ET AL.: ""PERP, an apoptosis-associated target of p53, is a novel member of the PMP-22/gas3 family", GENES DEV., vol. 14, no. 6, 2000, pages 704 - 718, XP002436523 * |
BIOCHEM. BIOPHYS. RES COMMUN, vol. 149, 1987, pages 960 |
BIOCHEM. J, vol. 355, 2001, pages 245 |
BIOCHEM. J., vol. 195, 1981, pages 639 |
BIOCHEMISTRY, vol. 32, 1993, pages 3131 |
BLOOD, vol. 65, 1985, pages 1349 |
BRITISH JOURNAL OF CANCER, vol. 39, 1976, pages 15 |
CANCER IMMUNO IMMUNOTHER., vol. 36, 1993, pages 373 |
CANCER IMMUNOL. IMMUNOTHER., vol. 36, 1993, pages 373 |
CANCER RES., vol. 46, 1986, pages 6489 |
CANCER RES., vol. 52, 1992, pages 3402 |
CANCER RES., vol. 56, 1996, pages 1118 |
CELL, vol. 33, 1983, pages 717 |
CELL, vol. 41, 1985, pages 479 |
CO M.S. ET AL.: "Genetically engineered deglycosylation of the variable domain increases the affinity of an anti-CD33 monoclonal antibody", MOL. IMMUNOL., vol. 30, no. 15, 1993, pages 1361 - 1367, XP002425227 * |
COHEN ET AL., PROC. NATL. ACAD SCI., USA, vol. 69, 1972, pages 2110 |
CURR. BIOL., vol. 13, 2003, pages 1985 |
CURRENT PROTOCOLS IN MOLECULAR BICALOGY, pages 1 - 34 |
CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, pages 1 - 34 |
CURRENT TOPICS IN MICROBIOLOGY AND IMINITNOLOGY, vol. 18, 1978, pages 1 |
CYLOTECHNOLOGY, vol. 3, 1990, pages 133 |
CYTOLECHNOLOGY, vol. 3, 1990, pages 133 |
CYTOTECHNOL., vol. 13, 1993, pages 79 |
CYTOTECHNOL., vol. 3, 1990, pages 133 |
CYTOTECHNOL., vol. 4, 1990, pages 173 |
CYTOTECHNOLOGY, vol. 3, 1990, pages 133 |
DNA CLONING: A PRACTICAL APPROACH, vol. I, 1985, pages 49 |
ELISA: "Monoclonal Antibodies-Principles and practice", 1996, ACADEMIC PRESS |
EUROPECM J IMMUNOLOGY, vol. 6, 1976, pages 511 |
GENE, vol. 17, 1982, pages 107 |
GENE, vol. 27, 1984, pages 223 |
GENE, vol. 33, 1985, pages 103 |
GENE, vol. 34, 1985, pages 315 |
GENE, vol. 38, 1985, pages 275 |
GENES & DEVELOPMENT, vol. 14, 2000, pages 704 |
GENES DEVELOP., vol. 4, 1990, pages 1288 |
GENETICS, vol. 39, 1954, pages 440 |
GENOME RES., vol. 7, 1997, pages 649, Retrieved from the Internet <URL:http://www.ncbi.nlm.nih.gov/Education/BLASTinfo/information3.html> |
HIROKAWA SHOTEN, BIOCONJUGATE DRUG, 1993 |
HYBRIDOMA, vol. 17, 1998, pages 559 |
IMMUNOL., vol. 85, 1995, pages 668 |
ISHIYAKU SHUPPAN, INFLAMMATION AND ANTI-INFLAMMATORY THERAPY, 1982 |
J BIAL. CHEM., vol. 271, 1996, pages 2966 |
J IMMUNOLOGY, vol. 123, 1979, pages 154 |
J. BACTERIOL., vol. 172, 1990, pages 2392 |
J. BIOCHEM., vol. 101, 1987, pages 1307 |
J. BIOCHEMISTRY, vol. 101, 1987, pages 1307 |
J. IMMUNOL. METHODS, vol. 167, 1994, pages 271 |
J. IMMUNOL., vol. 135, 1985, pages 1530 |
J. IMMUNOL., vol. 144, 1990, pages 1382 |
J. MOL. BIOL., vol. 112, 1977, pages 535 |
J. MOL. BIOL., vol. 16, 1966, pages 118 |
J. MOL., vol. 166, 1983, pages 1 |
J. MOL., vol. 215, 1990, pages 403 |
J. NATL. CANCER INST., vol. 80, 1988, pages 932 |
J. NATL. CANCER INST., vol. 80, 1988, pages 937 |
J. NUCL. MED., vol. 26, 1985, pages 1011 |
J: CLIN. ONCOL., vol. 2, 1984, pages 881 |
LOWE ET AL., PROC, NATL. ACAD SCI. USA, vol. 86, 1989, pages 8227 |
METHODS IN ENZYMOL, vol. 154, 1987, pages 3 |
MOL. CELL. BIOL., vol. 3, 1983, pages 280 |
MOLECULAR & GENERAL GENETICS, vol. 168, 1979, pages 111 |
MOLECULAR IMMTINOL, vol. 32, 1995, pages 249 |
NATURE BIOTECHNOL, vol. 15, 1997, pages 629 |
NATURE, vol. 227, 1970, pages 680 |
NATURE, vol. 256, 1975, pages 495 |
NATURE, vol. 276, 1978, pages 269 |
NATURE, vol. 322, 1988, pages 323 |
NATURE, vol. 329, 1987, pages 840 |
NUCLEIC ACID RES., vol. 25, 1997, pages 3389 |
NUCLEIC ACIDS RESEARCH, vol. 10, 1982, pages 6487 |
NUCLEIC ACIDS RESEARCH, vol. 11, 1989, pages 9494 |
NUCLEIC ACIDS RESEARCH, vol. 13, 1985, pages 4431 |
PAULSON ET AL., J. BIOL. CHEM, vol. 264, 1989, pages 17619 |
PROC. NATL. ACAD SCI. USA, vol. 69, 1972, pages 2110 |
PROC. NATL. ACAD SCI. USA, vol. 78, 1981, pages 1527 |
PROC. NATL. ACAD SCI. USA, vol. 82, 1985, pages 1242 |
PROC. NATL. ACAD SCI. USA, vol. 82, 1985, pages 4306 |
PROC. NATL. ACAD SCI. USA, vol. 82, 1985, pages 488 |
PROC. NATL. ACAD SCI. USA, vol. 84, 1987, pages 7413 |
PROC. NATL. ACAD. SCI. U.S.A., vol. 77, 1980, pages 4216 |
PROC. NATL. ACAD. SCI. USA, vol. 79, 1982, pages 6409 |
PROC. NATL. ACAD. SCI. USA, vol. 84, 1987, pages 7413 |
PROCEEDING OF THE SOCIETY FOR EXPERIMENTAL BIOLOGY AND MEDICINE, vol. 73, 1950, pages 1 |
PROTEIN ENGINEERING, Z, 1994, pages 1501 |
REITER ET AL., PROTEIN ENGINEERING, 1994, pages L 697 |
SANGER, F. ET AL., PROC. NATL. ACAD SCI. USA, vol. 74, 1977, pages 5463 |
SCIENCE, vol. 122, 1952, pages 501 |
SCIENCE, vol. 222, 1983, pages 778 |
SCIENCE, vol. 242, 1988, pages 423 |
See also references of EP1959009A4 * |
SEQUENCES OF PROTEINS OF IMMUNOLOGICAL INTEREST, 1991 |
SEQUENCES OF PROTEINS OF IMMUNOLOGICAL. INTEREST, 1991 |
SEQUENCES OFPROTEINS OF IMMUNOLGICAL INTEREST, 1991 |
SOMATIC CELL AND MOLECULAR GENETICES, vol. 12, 1986, pages 55 |
SOMATIC CELL AND MOLECULAR GENETICS, vol. 12, no. 6, 1986, pages 555 |
STRATEGIES, vol. 5, 1992, pages 81 |
THE JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, vol. 199, 1967, pages 519 |
TRENDS IN GLYCOSCIENCE AND GLYCATECHHOLOGY, vol. 11, 1991, pages 1 |
VIROLOGY, vol. 8, 1959, pages 396 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2019534844A (ja) * | 2016-09-08 | 2019-12-05 | ウリィ・テクノロジーズ・コーポレーション | clec14aに特異的に結合する脱糖化抗体及びその用途 |
CN109391434A (zh) * | 2017-08-11 | 2019-02-26 | 中兴通讯股份有限公司 | 参考信号的配置方法及装置 |
Also Published As
Publication number | Publication date |
---|---|
EP1959009A1 (en) | 2008-08-20 |
EP1959009A4 (en) | 2010-04-28 |
US20080267953A1 (en) | 2008-10-30 |
US8093362B2 (en) | 2012-01-10 |
JP5095416B2 (ja) | 2012-12-12 |
JPWO2007066698A1 (ja) | 2009-05-21 |
AU2006323706A1 (en) | 2007-06-14 |
AU2006323706A8 (en) | 2008-05-22 |
CA2632419A1 (en) | 2007-06-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3946256B2 (ja) | ヒトインターロイキン5受容体α鎖に対する抗体 | |
JP5425775B2 (ja) | 抗cd27抗体 | |
TWI501777B (zh) | 人類抗cd27單株抗體 | |
JP5586146B2 (ja) | ヘパリン結合上皮細胞増殖因子様増殖因子に結合するモノクローナル抗体 | |
JP5730570B2 (ja) | 抗システムascアミノ酸トランスポーター2(asct2)抗体 | |
JPWO2008114733A1 (ja) | 抗Claudin−4抗体 | |
JP5532401B2 (ja) | ヘパリン結合上皮細胞増殖因子様増殖因子に結合するモノクローナル抗体 | |
JP5812869B2 (ja) | 抗システムascアミノ酸トランスポーター2(asct2)抗体 | |
KR20120110141A (ko) | 항 IgA1 항체 | |
JP2022547850A (ja) | 抗tigit免疫阻害剤及び応用 | |
JP5651893B2 (ja) | 抗perp抗体 | |
US11912775B2 (en) | Anti-human CCR1 monoclonal antibody | |
WO2016063522A1 (ja) | 抗ヒトGas6モノクローナル抗体 | |
WO2007066698A1 (ja) | 抗perp遺伝子組換え抗体 | |
JP2001046066A (ja) | 新規な相補性決定領域を有するヒトvegf受容体kdrに対する抗体 | |
JP3679406B2 (ja) | 遺伝子組換え抗体 | |
AU2014357450B2 (en) | Antibodies targeting B-cell receptor complex membrane bound IgM and uses thereof | |
KR20230114745A (ko) | 신규 항-cd47 항체 및 이의 용도 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2007549159 Country of ref document: JP Kind code of ref document: A |
|
REEP | Request for entry into the european phase |
Ref document number: 2006834140 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006834140 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006323706 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2006323706 Country of ref document: AU Date of ref document: 20061206 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2632419 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |